Register REGISTER
2015 AACR - CE Information

Continuing Medical Education (CME)

 

ACCREDITATION STATEMENT

The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.

CREDIT DESIGNATION STATEMENT

AACR has designated this live activity for a maximum of 23.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CLAIMING (CME) CREDIT

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey (available here as the meeting approaches). Certificates will only be issued to those who complete the survey.  Your CME certificate will be sent to you via email after the completion of the activity.

STATEMENT OF EDUCATIONAL NEED, TARGET AUDIENCE, AND LEARNING OBJECTIVES

As stated by Blasberg and Piwnica-Worms in 2012, the field of molecular imaging (i.e., visualizing both normal and abnormal molecular and cellular processes in vivo using non-invasive imaging strategies) was named as such in the late-1990’s.  Although heavily rooted in molecular and cell biology, many of the advances in molecular imaging occurred independently of the large advances in molecular biology and genetics in the 1980’s and early 1990’s.  The field of imaging is growing and evolving to not only benefit cancer research and treatment at the phenotypic, diagnostic, anatomical, and physiological levels, but also at the cellular/molecular level.  Molecular imagers are able to visualize the molecular basis of the disease and treatment efficacy in vivo.  To develop this field that is so closely intertwined with the benchwork of cancer research and the personalized treatment and monitoring of therapeutic efficacy at the bedside, Blasberg and Piwnica-Worms place incredible value on collaboration.  They said that for both the molecular imaging and cancer research/treatment fields to flourish, there is a need for “radiologic scientists and clinical researchers to share a common conceptual framework, vocabulary, and approach to genomic and proteomic science.”  Blasberg called for this in a similar review article in 2003 stating, “Continued success in the future depends on bringing the imaging disciplines closer together, as well as further involvement with our molecular and cell biology colleagues.”

According to the 2014 American Association for Cancer Research Cancer Progress report, between August 1, 2013 and July 31, 2014, the FDA approved new uses for two imaging agents.  As technological advances in molecular imaging bring sensitivity and resolution to the molecular and cellular levels, it is becoming increasingly critical for imagers to better understand the needs of the cancer research and treatment community to not only optimize technologies, but to translate these advances into clinical applications, diagnostics, efficacy measure in vivo, and drug delivery.  Reciprocally, it is critical for cancer researchers and physicians to learn from imaging scientists about the power behind emerging technologies and how these technologies can better inform cancer research, clinical trial design, less invasive and earlier diagnosis, and treatment options.

After participating in this CME activity, physicians should be able to:

  1. Identify emerging technologies in molecular imaging of cancer, as well as, identify innovative cancer therapies guided by molecular imaging in cancer treatment.
  2. Review the utility of mouse models of cancer and how they impact cancer imaging research.
  3. Articulate examples of theranostics in cancer research and treatment.
  4. Identify how molecular imaging is being used in diagnostics and in the visualization of the tumor microenvironment, immune cell migration, inflammation, exosomes, and metabolism of the cancer cell.
  5. Provide examples of how molecular imaging can inform clinical trial design and outcomes.
  6. Discuss the challenges and opportunities in imaging certain cancer types, i.e. prostate cancer.
  7. Identify new approaches to image segmentation and image feature extraction for correlation with “big data” and other ‘omics analysis strategies.

DISCLOSURE STATEMENT

It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.

ACKNOWLEDGMENT OF FINANCIAL OR OTHER SUPPORT

This activity is supported by grants and will be disclosed at the activity. 

QUESTIONS ABOUT CME?

Please contact the Office of CME at (215) 440-9300 or cme@aacr.org.